Latest News
-

AMT-130 at Four Years: Hopeful Signs, Complex Controls
⏱️ 12 min read
uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.
-

New antibody reveals dangerous parts of huntingtin protein
⏱️ 6 min read
A new antibody lets scientists identify neurons that are going to die after producing mutant huntingtin
-

Safety trials add crucial piece to gene silencing jigsaw
⏱️ 10 min read
Three trials of drugs to 'silence' the HD gene in monkeys show they hit the target safely. Human trials coming soon.
-

Melatonin treatment success in HD mice
⏱️ 9 min read
Melatonin delays disease onset and extends survival in Huntington's disease mice – could it do the same for patients?
-

HD World Congress 2011: a retrospective
⏱️ 8 min read
HDBuzz looks back at the highlights of the Huntington's disease world congress 2011 in Melbourne
-

HDAC inhibitors and a possible 'blood biomarker'
⏱️ 9 min read
HDAC inhibitors explained, plus how new HDAC-related Huntington's disease research might help us find biomarkers
-

HD just got cilia
⏱️ 5 min read
Huntington's disease just got cilia: huntingtin protein affects tiny but important hairs on cells called cilia
-

Gene silencing takes a targeted step forward
⏱️ 6 min read
Targeting the mutant Huntington's disease gene for silencing, while leaving the healthy gene untouched
-

Prana Biotech's new trial of PBT2 in Huntington's disease: the lowdown
⏱️ 7 min read
Prana Biotech's PBT2 trial in Huntington's disease: what we know so far & what copper has to do with the mutant prote
-

Oz Buzz Video: Day 2
⏱️ 25 min read
The final day of Oz Buzz: the nightly news, interviews and features presentation from the HD World Congress 2011
-

Oz Buzz Video: Day 1
⏱️ 32 min read
Day 1 of Oz Buzz: the nightly news, interviews and features presentation from the HD World Congress 2011
HDBuzz Trial Tracker
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
Previously featured
-
AMT-130 at Four Years: Hopeful Signs, Complex Controls
-
September 2026: This month in Huntington’s disease research
-
Studying Stutters: What 900,000 genomes teach us about growing DNA repeats
-
Highlighting Mental Health Disparities in Indigenous Communities Affected by Huntington’s Disease
-
Encouraging news from Skyhawk, as SKY-0515 Phase 1/2 data continues to hold promise
Follow HDBuzz
Sign up to our monthly email summary by entering your email address on our mailing list page.
Suggest an article
Is there something you want us to write about? Tell us about it here. We consider all suggestions but can’t promise to write content about any particular suggestion.
